Gemtuzumab ozogamicin is an anti-cancer medicine used to treat acute myeloid leukemia (AML). It is a monoclonal antibody that binds to a specific cell surface protein called CD33, found on the surface of many types of leukemia cells. This allows the drug to target and kill leukemia cells. Gemtuzumab ozogamicin is usually given by IV infusion over a period of several hours, and may be combined with other cancer treatments. Common side effects include fever, chills, nausea, headache, and muscle pain.
Gemtuzumab ozogamicin, also known by the brand name Mylotarg, is a medication used to treat certain types of leukemia [1]. Here's a breakdown of some key points about it:
- Type of drug: It's an antibody-drug conjugate (ADC), which means it combines a monoclonal antibody with a chemotherapy drug [2].
- What it targets: The antibody targets a protein called CD33, found on the surface of many leukemia cells [2, 3].
- Conditions it treats: It's specifically approved to treat acute myeloid leukemia (AML) that is CD33-positive. This means the leukemia cells have the CD33 protein on their surface [4]. It can be used for newly diagnosed AML or for AML that has come back (relapsed) or not responded to other treatment (refractory) [4].
Important to note:
- Gemtuzumab ozogamicin has a complex history. It was initially withdrawn from the market due to safety concerns but was later re-approved with a lower dose and different treatment regimen [2, 5].
- Like many medications, it can have serious side effects, including liver damage. It's important to discuss the risks and benefits with a doctor before taking it [4].
If you have further questions about gemtuzumab ozogamicin, it's important to consult with a healthcare professional.